Donepezil for mild cognitive impairment in Parkinson’s disease

We investigated the efficacy of donepezil for mild cognitive impairment in Parkinson’s disease (PD-MCI). This was a prospective, non-randomized, open-label, two-arm study. Eighty PD-MCI patients were assigned to either a treatment or control group. The treatment group received donepezil for 48 weeks...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Sci Rep
Asıl Yazarlar: Baik, Kyoungwon, Kim, Seon Myeong, Jung, Jin Ho, Lee, Yang Hyun, Chung, Seok Jong, Yoo, Han Soo, Ye, Byoung Seok, Lee, Phil Hyu, Sohn, Young H., Kang, Seung Wan, Kang, Suk Yun
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Nature Publishing Group UK 2021
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7910590/
https://ncbi.nlm.nih.gov/pubmed/33637811
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-021-84243-4
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller